A Phase 3 Open-label Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older Homozygous or Heterozygous for the F508del-CFTR Mutation

C
Clement Ren, MD

Primary Investigator

Recruiting
6 years - 100 years
All
Phase N/A
1 Location

Brief description of study

The purpose of this study is to evaluate the long-term safety and tolerability of TEZ/IVA in subjects with cystic fibrosis aged 6 years and older, who are homozygous or heterozygous for F508del mutation.

Detailed description of study

The purpose of this study is to evaluate the long-term safety and tolerability of tezacaftor in combination with ivacaftor (TEZ/IVA) in subjects with cystic fibrosis (CF) aged 6 years and older, homozygous or heterozygous for the F508del mutation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: cystic fibrosis
  • Age: 6 years - 100 years
  • Gender: All

Inclusion Criteria
Male and female subjects with CF aged 6 years and older, who completed Study 113
Part B or Study 115 and are
homozygous for F508del (F/F),
heterozygous for F508del and a second allele with a residual CFTR-function
mutation (F/RF), or
heterozygous for F508del and a second allele that has been shown to be
responsive to TEZ/IVA
Exclusion Criteria
History of any comorbidity that, in the opinion of the investigator, might confound the results
of the study or pose an additional risk in administering study drug to the subject
Pregnant and nursing females
Sexually active subjects of reproductive potential who are not willing to follow the
contraception requirements
History of drug intolerance in the parent study that would pose an additional risk to the
ubject in the opinion of the investigator, and which should be discussed with the Vertex
medical monitor
History of poor compliance with study drug and/or procedures in a previous study as deemed
by the investigator
Ongoing participation in another study with investigational drug


Additional Information:
Participants will not be paid for their participation.

Updated on 01 Aug 2024. Study ID: 1802366632

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center